The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Thromboprophylaxis in patients with VWD and COVID-19
Suchitra Acharya, MD, MBBS, Northwell Health, New Hyde Park, New York, NY, discusses the use of prophylactic anticoagulants in patients with rare bleeding disorders infected with COVID-19. Adults with COVID-19 are at a higher risk of developing thrombosis and are consequently administered a thromboprophylaxis. For patients with rare bleeding disorders including type III von Willebrand disorder, replacement factor concentrates are necessary to stabilize factor levels to safely administer the prophylactic anticoagulant. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
